Walgreens, Prothena in pact for early-stage Alzheimer’s trial
phototechno

Walgreens (NASDAQ:WBA) and clinical-stage biotech Prothena (NASDAQ:PRTA) have joined hands to accelerate the patient identification and recruitment for the latterâs ongoing early-stage trial for Alzheimerâs candidate PRX012, the companies announced Thursday.
The Phase 1 study named ASCENT-2 is designed to evaluate the safety and tolerability of the anti-amyloid beta antibody in patients with Alzheimerâs disease.

Currently, single ascending dose (SAD) and multiple ascending dose (MAD) phases of ASCENT-2 are underway, with topline data expected by the end of the year.
âAt Prothena, weâre excited about PRX012 and the impact it could have as a next-generation Alzheimerâs disease treatment with the potential for more convenient administration for patients and caregivers,â medical chief of Prothena (PRTA), Hideki Garren remarked.

Walgreens (WBA) cited challenges in patient enrollment in launching its clinical trial business in June 2022.

According to Seeking Alpha contributor Geoffrey Seiler, the company is aggressively investing in its healthcare segment as it seeks to become an integrated player in the healthcare-pharmacy services business.